To the Editor:
We thank Dr. Ng and his colleagues for their valuable comments on our article. 1 Our study aimed to answer two questions. First, does a first-night effect exist in childhood sleep; and second, is single-night polysomnography adequate in assessing children with sleep-related disordered breathing? We agree that our sample population was biased toward obese children, and we fully acknowledged that limitation in our discussion. This limitation may have some bearing to the second question our study tried to answer, but we do not think the presence of the first-night effect would have been affected by the body mass index of the subjects.
The diagnostic cutoff for childhood obstructive sleep apnoea (OSA) is still very much a controversial issue. Dr. Ng and colleagues argued that the apnea-hypopnea index (AHI) would have been a better diagnostic parameter for diagnosing OSA. They suggested that we use a cutoff of AHI Ͼ 1.5, and they based their suggestion on a letter to the editor by Witmen et al, 2 who reviewed the original overnight polysomnographic data of 41 children in the study by Marcus and colleagues 3 for obstructive hypopneas. Witmen et al 2 concluded that obstructive hypopneas are uncommon, but their data are limited in that they are based on older technology. Some authorities including reviewers of our article would recommend the use of AHI cutoffs of 2, 3, and 5. Until we have evidence-based science to support that an AHI Ͼ 1.5 corresponds to significant long-term morbidity or even mortality, using a more conventional diagnostic cutoff (obstructive apnea index Ͼ 1) is still acceptable. We agree with Dr. Ng and colleagues that if resources allow, attended polysomnography remains the "gold standard." First of all, as Mahler et al 1 described in the introduction to the article, the pathogenesis of COPD consists of several mediators other than IL-8. Target molecules in COPD involve tumor necrosis factor, interferon-␥, and IL-6 as cytokines, CCL2, CCL3, and CCL13 as chemokines, and several proteinases such as matrix metalloproteinase and neutrophil elastase. 2,3 Thus, only IL-8 blockade itself may not have a great influence on disease activity. We are also concerned about the relatively low circulatory levels of the cytokine (ie, Ͻ 50 pg/mL) in the subjects examined. Alternatively, these data may indicate that IL-8 does not contribute to the symptoms of COPD in stable stages of the disease. Instead, we want to be informed of any previous studies in the literature in which the possible correlations between IL-8 and an exacerbated phase of COPD have been demonstrated.
In the "Results" section, the differences in the transition dyspnea index total score between the fully human monodonal IgG 2 antibody directed against interleukin-8 (ABX-IL-8)-treated group and the placebo group showed significance only at week 2 in their follow-up period. The results suggest that an IL-8 neutralizing strategy may be effective only for the short-term use of a chemoattractant of effector cells (neutrophils) in patients with COPD. Since COPD is one of the representative chronic disorders, the results by Mahler and coworkers cannot satisfy the patients and physicians.
Finally, we think the administration of ABX-IL-8 by inhalation should lead to better, more optimistic outcomes for subjects. The majority of reports 4,5 have shown elevated IL-8 levels in the sputum samples of patients with COPD. However, as we have confirmed in murine models, the elevated levels of the local expression of proinflammatory cytokines, such as IL-1␤, and chemokines, such as keratinocyte chemoattractant, macrophage inflammatory protein-1␣, and macrophage chemoattractant protein-1, during lung inflammation are not always paralleled by systemic circulatory levels of the molecules (unpublished obser-vation). Future clinical studies using an inhaled type of IL-8 antagonistic agent may provide comfort for patients with this troublesome disease. 
Ken-ichiro

To the Editor:
We appreciate the interest expressed by Dr. Inoue and colleagues in our study evaluating monoclonal therapy recognizing interleukin (IL)-8 in patients with COPD. We agree that recruitment of subjects and performance of placebo-controlled trials in patients with symptomatic COPD are both difficult and challenging. However, such randomized controlled trials are critical for providing the scientific evidence to assess new therapies for patients with COPD.
As noted in the subtitle and in the "Discussion," this was a pilot study to investigate monoclonal antibody therapy directed against IL-8 to treat the inflammatory component of the disease. As suggested by Dr. Inoue and colleagues, there are many unanswered questions about the role and the importance of the numerous mediators of inflammation in COPD. This study was performed to explore treatment of a new target (IL-8) that modulates inflammation in this condition. The results of this study showed that three infusions of monoclonal antibody recognizing IL-8 (ABX-IL8) were safe and well tolerated compared with placebo. These safety data are quite reassuring. Moreover, these data provide preliminary information so that additional studies can be designed and performed to assess the appropriate dose of ABX-IL8, to consider whether inhaled administration of ABX-IL8 may be beneficial (as suggested by Dr Inoue and associates), and to examine which outcome measures are appropriate to evaluate biological agents in COPD.
Donald A. Mahler, MD Gregory M. Bell, MD Lebanon, NH
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal. org/misc/reprints.shtml).
Correspondence to : Donald A. Mahler, MD, One Medical Center Dr, Lebanon, 
Striving for Excellent End-of-Life Care
To the Editor:
The editorial in CHEST (November 2004) 1 by Wood and Marik regarding how to improve end-of-life care in the ICU was welcome and timely, well-supported, and well-written. I believe that their first two points regarding customizing care and incorporating post-hospital discharge planning into ICU care are right on the mark.
But I believe that they are shy of the mark on their third point about "educating the public." I think that this is where we as intensivists and all of medicine have failed the public through our own lack of training and education in the delivery of end-of-life care. Much of the problem with providing futile intensive care lies far "upstream" from the ICU, in the offices of physicians who are taking care of patients with chronic, progressive, and ultimately fatal diseases such as cerebrovascular disease, congestive heart failure, dementia, COPD, and cancer, among others.
End-of-life care has been a hot topic in medicine for at least 10 years now. The Robert Wood Johnson Foundation and other charitable organizations have poured huge sums of money into efforts to improve end-of-life care. Much has been learned in these years, but I think the most important lesson can be summed up as follows fairly simply: most physicians and nurses are inadequately trained to provide high-quality, compassionate endof-life care. Most of us have had no formal training in advance care planning, communicating bad news, communicating about and identifying the goals of care, pain management, medical futility, and legal, spiritual, and social issues of patients nearing the end of life. Is it any wonder that the public is not educated? We have failed to educate ourselves to be capable of educating the public.
I do not mean to imply that there are not thousands of physicians who are excellent and well-trained in these areas. There are. But I do not have to tell the readers of this journal that, first, we are not as well trained as we would like to be, and, second, that those who are upstream from us are even less likely to be as attuned to these issues and are more uncomfortable in dealing with them. And above and beyond these issues are the economic disincentives that provide pressure against doing the right thing, even when the medical team is well-trained.
Education in Palliative and End-of-life Care (The EPEC Project 2 ) is a training program that was developed by the American Medical Association with support from the Robert Wood Johnson Foundation to bridge the gap in training in end-of-life care that the vast majority of physicians have experienced. It was designed as an intensive 2-day educational experience to bring competence to physicians in all of the major aspects of end-of-life care. It does not turn physicians into palliative care experts any more than advanced cardiac life support turns us into cardiologists, but it does provide a solid foundation and basic competencies in end-of-life care, and it allows us to teach and learn with primary care physicians, specialists, nurses, clergy, social workers, and others. It is a powerful course, one that can lead to tears of recognition or uneasiness when we recognize ourselves in others eyes, and to joy when we rediscover many of the profoundly human reasons why we are so privileged to be physicians.
I strongly support the advocacy by Marik and Wood 1 for better
